ANZCTR search results

In this study up to 20 subjects will be enrolled at a single study centre. The study will consist of a screening period, placebo run-in period, treatment period and follow-up period. Participants will all have active keloids. Participants will be provided with PXS-6302 to apply topically (and placebo if >1 keloid requires treatment) for a period of 3 months. Safety will be assessed as frequency/type of adverse events. Exploratory measures to assess changes in the keloid (size/symptoms) will also be used.

This study aims to assess the Safety, Biodistribution, and Dosimetry of [68Ga]Ga-A9-6217 in Participants with Select Advanced or Metastatic Solid Tumors. [68Ga]Ga-A9-6217 is a radioactive tracer that is used to assist with visualising potential tumors. Who is it for? You may be eligible to join this study if you are aged 18 years or above with advanced or metastatic breast cancer, prostate cancer, non-small cell lung cancer, small cell lung cancer or colorectal cancer. Study details All participants in this study will be asked to attend a Screening Visit which may need to take place over more than 1 day. Participants deemed eligible following their screening visits will be required to attend a single session that lasts for approximately 6 hours to complete at least 2 full body PET scans, which will include an injection of the tracer ([68Ga]Ga-A9-6217) and collection of blood and urine samples at various timepoints. Participants may be asked to complete 2 additional scans and will then be followed up for 2 days, including general monitoring. It is hoped that this study will help determine if [68Ga]Ga-A9-6217 is a safe and effective tracer that can be used in diagnosis or monitoring of tumours in individuals with cancer.

Assessment of bone mineral density on pre vs post contrast computed tomography compared with dual energy x-ray. Many patients have abdominal CT imaging performed to assess for other pathology. If bone mineral density can be opportunistically assessed on these studies with or without IV contrast then patients can be screened for osteoporosis or the need for a formal dual energy x-ray scan to assess for osteoporosis. Opportunistic screening for osteoporosis through CT scans may facilitate earlier diagnosis and treatment, reducing complications, at no additional cost to patients.

People with severe mental illness are much more sedentary than the general population, and therefore more susceptible to life limiting diseases such as cardiovascular disease and clinical obesity. This study aims to assess the feasibility and usability of an app and wrist wearable to promote physical activity snacks (<10min in duration) in people with severe mental illness. We hypothesis that the app will be feasible and acceptable for people with severe mental illness. We also hypothesise that prompting people with severe mental illness to do activity 'snacks' will increase their physical activity levels, decrease sedentary behaviour, and improve quality of life.

This study aims to investigate the impact of plan parameters and optimisation approaches on plan monitor units (MUs) and corresponding physics quality assurance (QA) results. Who is it for? Patients who have been diagnosed with intact brain metastases and/or post-operative cavities after resection of brain metastatic disease, and planned with HyperArc and treated on the stereotactic linear accelerator at Canberra Region Cancer Centre from September 2022 to March 2025 will be retrospectively analysed for this study. Study details Once participants are deemed eligible, their existing radiation treatment plans will be randomly selected to provide a wide range of plan characteristics such as number of lesions, size of lesions, shape of lesions, distance from isocentre, proximity to healthy organs and use of optimisation structures. These plans will be de-identified and replanned, changing one variable at a time to observe the results on plan complexity (MUs) and physics QA results. These plans will be ensured clinical acceptability by the principal investigator. After replanning, the impact of plan characteristics on plan complexity and physics QA results will be observed and from that data, MU limits will be developed which are tailored on specific plan characteristics. It is hoped that the results from this study will provide a better understanding of the change in complexity of HyperArc SRS plans depending on particular plan characteristics and see the implementation of MU limits result in a more seamless SRS planning workflow which balances clinical acceptability with deliverability and safety.

This randomised controlled trial will investigate the feasibility of an allied health assistant providing physiotherapy to people with cognitive impairment following hip fracture surgery. The allied health assistant will provide all therapy to people in hospital. All therapy will be prescribed by a physiotherapist and will include daily walking, standing and seated exercises. We hypothesise that it is feasible for allied health assistants to provide physiotherapy to people with cognitive impairment after hip fracture surgery.

PACE-RURAL introduces a novel, risk-based pathway designed to ensure that people with musculoskeletal conditions receive appropriate care which matches their needs. PACE-RURAL is about getting the right care to people at the right time. For example, people with reasonably straightforward presentations who should recover well are supported through a musculoskeletal e-hub featuring guideline-based resources and simple exercise programs, enabling effective self-management. Those at greater risk of persistent pain or disability will be referred to expert musculoskeletal clinicians (e.g., specialist physiotherapists) for a comprehensive assessment. Depending on their needs, care may involve shared management with primary healthcare providers (using telehealth when appropriate), specialist-led care, or referrals for services such as psychology or surgical opinions.

The aim of this project is to examine whether a self-guided version of the ultra-brief digital treatment, the Single Session Course, is effective at reducing symptoms of depression and anxiety. People will be randomly allocated to receive treatment immediately or after 9-weeks. The primary outcomes are depression and anxiety symptoms, and the primary timepoint is 9-weeks. We expect the treatment to be associated with larger symptom reductions compared to a waitlist control.

This study aims to evaluate the toxicity and quality of life (QOL) outcomes associated with 5-fraction stereotactic ablative radiotherapy (SABR) for high risk and/or node positive prostate cancer. Who is it for? You may be eligible to join this study if you are aged 18 years or above and have high risk and/or node positive prostate cancer. Study details: Traditional radiotherapy for high risk and/or node positive prostate cancer typically involves four to eight weeks of daily treatment, with androgen deprivation therapy, Recent studies have shown that using fewer but larger doses of radiation, i.e. 5-treatment SABR, is just as effective and safe, and this has now become one of the standard radiotherapy schedules for intermediate risk prostate cancer. The question then is whether we can further reduce the number of treatments for prostate SABR while maintaining the cancer control rate and minimizing side effects for high risk and/or node positive prostate cancer. This is an appealing option from a patient convenience and healthcare cost-saving point of view. In this Australian phase 2 trial of 5-treatment prostate and pelvic SABR, we aim to evaluate the efficacy, toxicity and quality of life outcomes of this treatment.

This study aims to investigate the feasibility and tolerability of bright light therapy for delirium prevention in hospitalized adults with advanced cancer. Who is it for? You may be eligible to participate in this study if you are a male or female 18 years or older, have diagnosis of advanced cancer and are admitted to a palliative or oncology unit at participating investigational sites and do not present with delirium upon admission. Study details Eligible participants will be randomized to one of two groups: Group 1 - Re-Timer group and Group 2 - Standardized supportive care. Group 1 will have the Re-Timer device applied for a single continuous time of 60 minutes between 7am to 10am daily, until delirium occurrence, discharge death or a minimum of seven days if participants remain in hospital. In addition, standardized supportive care, according to NICE delirium clinical guidelines will be provided, as well as standardized evening light exposure, defined as dimmed hospital room lighting from 11:00pm until the next morning at 6:30am, will be applied for the duration of treatment. Participants randomized to Group 2 will receive Standardized supportive care only. Participants in Group 1 will be followed up daily to assess feasibility and tolerability of Bright light therapy, preliminary efficacy, melatonin, sleep and economic feasibility. It is hoped that this research project will determine whether bright light therapy is effective at regulating circadian rhythms and delirium prevention in people with advanced cancer.